← Leaderboards
Sudha Seshadri
Boston University Medical Campus
$50,696,682
Attributed
$100,536,673
Total exposure
24
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $18.6M · FY2009–25$20M$15M$10M$5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$138,440,330 · 26
By mechanism
R01$52,637,342 · 10
U19$23,106,653 · 1
U01$19,066,402 · 4
P30$18,852,504 · 3
RF1$13,700,811 · 3
R56$3,529,440 · 1
Top collaborators
- Myriam Fornage21 shared
- Charles Decarli11 shared
- Eric A Boerwinkle8 shared
- Philip L De Jager8 shared
- Anita L Destefano8 shared
- Vasan S. Ramachandran8 shared
- Ellen M Wijsman8 shared
- Rhoda Au7 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Jeffrey H Samet$129,777,857
- Catherine E. Costello$27,592,140
- David M Center$53,621,178
- Thomas E Van Dyke$23,853,105
- Darrell N. Kotton$37,875,782
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposGeneticCohortS DiseaseDementiaMagnetic Resonance ImagingSamplingBrainPersonsParticipantCommunitiesCognitiveFundingRisk FactorsBiological MarkersCognitionGenomicsPathway InteractionsImageResourcesCollaborationsPre-ClinicalGenome Wide Association StudyResearch Personnel
Grant awards (102)
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$4,853,251
U19 · FY2025 · AG
South Texas Alzheimer's Disease Center$2,946,508
P30 · FY2025 · AG · contact PI
Precursors of Stroke Incidence and Prognosis$1,456,892
R01 · FY2025 · NS
Multiethnic Validation of VCID biomarkers in South Texas$949,277
U01 · FY2025 · NS
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$806,739
U19 · FY2025 · AG
South Texas Alzheimer's Disease Center Administrative Core$561,046
P30 · FY2025 · AG · contact PI
South Texas Alzheimer's Disease Center Genetics and Multiomics Core$243,004
P30 · FY2025 · AG · contact PI
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$110,683
U19 · FY2025 · AG
International Workshops to Grow and Support Global Network of Interdisciplinary Researchers Fluent in Neurology, Brain Imaging, Epidemiology, Genetics, Multiomics, and Ethics$50,000
R13 · FY2025 · AG · contact PI
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$8,610,822
U19 · FY2024 · AG
South Texas Alzheimer's Disease Center$2,945,927
P30 · FY2024 · AG · contact PI
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and Resilience$1,796,289
R01 · FY2024 · AG · contact PI
Precursors of Stroke Incidence and Prognosis$1,401,859
R01 · FY2024 · NS
Multiethnic Validation of VCID biomarkers in South Texas$1,184,613
U01 · FY2024 · NS
South Texas Alzheimer's Disease Center Administrative Core$561,046
P30 · FY2024 · AG · contact PI
South Texas Alzheimer's Disease Center Genetics and Multiomics Core$243,004
P30 · FY2024 · AG · contact PI
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$8,725,158
U19 · FY2023 · AG
South Texas Alzheimer's Disease Center$2,945,345
P30 · FY2023 · AG · contact PI
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and Resilience$1,796,274
R01 · FY2023 · AG · contact PI
Precursors of Stroke Incidence and Prognosis$1,509,443
R01 · FY2023 · NS
Multiethnic Validation of VCID biomarkers in South Texas$1,192,048
U01 · FY2023 · NS
South Texas Alzheimer's Disease Center Administrative Core$561,046
P30 · FY2023 · AG · contact PI
South Texas Alzheimer's Disease Center Genetics and Multiomics Core$243,004
P30 · FY2023 · AG · contact PI
South Texas Alzheimer's Disease Center$2,944,764
P30 · FY2022 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,147,504
U01 · FY2022 · AG
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and Resilience$1,924,622
R01 · FY2022 · AG · contact PI
Ventricular-vascular coupling in the elderly: lifecourse determinants, trajectories, and prognostic significance$563,941
R01 · FY2022 · HL
South Texas Alzheimer's Disease Center Administrative Core$561,046
P30 · FY2022 · AG · contact PI
South Texas Alzheimer's Disease Center Genetics and Multiomics Core$243,004
P30 · FY2022 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$32,137
U01 · FY2022 · AG
SARS-CoV-2 and Precursors of Alzheimer's Disease and Related Dementias: An Ultrahigh Field (7T) MRI Study in a Diverse Multinational Cohort$3,529,440
R56 · FY2021 · AG · contact PI
South Texas Alzheimer's Disease Center$3,014,460
P30 · FY2021 · AG · contact PI
Multiethnic Validation of VCID biomarkers in South Texas$2,412,788
UF1 · FY2021 · NS
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,153,560
U01 · FY2021 · AG
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and Resilience$1,896,088
R01 · FY2021 · AG · contact PI
South Texas Alzheimer's Disease Center Administrative Core$582,546
P30 · FY2021 · AG · contact PI
South Texas Alzheimer's Disease Center Genetics and Multiomics Core$256,754
P30 · FY2021 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$128,552
U01 · FY2021 · AG
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$112,663
U01 · FY2021 · AG
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and Resilience$2,243,953
R01 · FY2020 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,158,021
U01 · FY2020 · AG
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham Cohorts$1,992,571
R01 · FY2020 · AG · contact PI
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$974,558
UH3 · FY2020 · NS · contact PI
Precursors of Stroke Incidence and Prognosis$799,249
R01 · FY2020 · NS · contact PI
Alzheimers-focused Administrative Supplement to Enhance the Imaging Genomics of the Aging Brain Project$392,341
R01 · FY2020 · AG
ADSP Follow-up in Multi-Ethnic Cohorts via Endophenotypes, Omics & Model Systems$298,028
U01 · FY2020 · AG · contact PI
Plasma Proteome and Risk of Alzheimer Dementia and Related Endophenotypes in the Framingham Study$2,730,110
RF1 · FY2019 · AG
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham Cohorts$2,404,965
R01 · FY2019 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,164,820
U01 · FY2019 · AG
Plasma Proteome and Risk of Alzheimer Dementia and Related Endophenotypes in the Framingham Study$1,469,265
RF1 · FY2019 · AG
MRI, Cognitive, Genetic and Biomarker Precursors of AD & Dementia in Young Adults$1,004,154
R01 · FY2019 · AG
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$989,999
UH3 · FY2019 · NS · contact PI
Precursors of Stroke Incidence and Prognosis$818,469
R01 · FY2019 · NS · contact PI
Preclinical AD: Correlates of Amyloid, Tau PET and fcMRI in Framingham Gen 3 Young Adults$618,284
R01 · FY2019 · AG · contact PI
ADSP Follow-up in Multi-Ethnic Cohorts via Endophenotypes, Omics & Model Systems$374,449
U01 · FY2019 · AG · contact PI
Cognitively Healthy Nonagenarians in the Cross Cohort Collaboration (CCC)$6,118,496
RF1 · FY2018 · AG · contact PI
Identification of a missing key element underlying apoE2 neuroprotection in Alzheimer's disease and the aging brain$3,382,940
RF1 · FY2018 · AG
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham Cohorts$2,639,239
R01 · FY2018 · AG · contact PI
Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches$2,233,154
U01 · FY2018 · AG
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$1,080,940
UH3 · FY2018 · NS · contact PI
MRI, Cognitive, Genetic and Biomarker Precursors of AD & Dementia in Young Adults$1,026,714
R01 · FY2018 · AG
Precursors of Stroke Incidence and Prognosis$821,792
R01 · FY2018 · NS · contact PI
Preclinical AD: Correlates of Amyloid, Tau PET and fcMRI in Framingham Gen 3 Young Adults$622,745
R01 · FY2018 · AG · contact PI
MRI, Cognitive, Genetic and Biomarker Precursors of AD & Dementia in Young Adults$321,397
R01 · FY2018 · AG
ADSP Follow-up in Multi-Ethnic Cohorts via Endophenotypes, Omics & Model Systems$320,303
U01 · FY2018 · AG · contact PI
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham Cohorts$2,811,730
R01 · FY2017 · AG · contact PI
MRI, Cognitive, Genetic and Biomarker Precursors of AD & Dementia in Young Adults$1,038,541
R01 · FY2017 · AG
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$1,001,222
UH2 · FY2017 · NS · contact PI
Precursors of Stroke Incidence and Prognosis$828,217
R01 · FY2017 · NS · contact PI
Preclinical AD: Correlates of Amyloid, Tau PET and fcMRI in Framingham Gen 3 Young Adults$620,677
R01 · FY2017 · AG · contact PI
CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample$608,143
U01 · FY2017 · AG · contact PI
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham Cohorts$167,951
R01 · FY2017 · AG · contact PI
CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample$110,000
U01 · FY2017 · AG · contact PI
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham Cohorts$2,322,345
R01 · FY2016 · AG · contact PI
MRI, Cognitive, Genetic and Biomarker Precursors of AD & Dementia in Young Adults$1,063,951
R01 · FY2016 · AG
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$1,037,671
UH2 · FY2016 · NS · contact PI
Precursors of Stroke Incidence and Prognosis$861,530
R01 · FY2016 · NS · contact PI
CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample$749,083
U01 · FY2016 · AG · contact PI
ADSP Follow-up in Multi-Ethnic Cohorts via Endophenotypes, Omics & Model Systems$634,356
U01 · FY2016 · AG · contact PI
Preclinical AD: Correlates of Amyloid, Tau PET and fcMRI in Framingham Gen 3 Young Adults$621,485
R01 · FY2016 · AG · contact PI
AD Gene Discovery: Exome Chip, New Endophenotypes & Functional Studies in CHARGE$557,013
R01 · FY2016 · AG · contact PI
Epidemiology of Dementia in the Framingham Study$1,308,091
R01 · FY2015 · AG · contact PI
MRI, Cognitive, Genetic and Biomarker Precursors of AD & Dementia in Young Adults$1,048,692
R01 · FY2015 · AG
CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample$735,979
U01 · FY2015 · AG · contact PI
Preclinical AD: Correlates of Amyloid, Tau PET and fcMRI in Framingham Gen 3 Young Adults$630,377
R01 · FY2015 · AG · contact PI
AD Gene Discovery: Exome Chip, New Endophenotypes & Functional Studies in CHARGE$545,165
R01 · FY2015 · AG · contact PI
Epidemiology of Dementia in the Framingham Study$1,418,912
R01 · FY2014 · AG · contact PI
CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample$779,712
U01 · FY2014 · AG · contact PI
AD Gene Discovery: Exome Chip, New Endophenotypes & Functional Studies in CHARGE$582,184
R01 · FY2014 · AG · contact PI
AD Gene Discovery: Exome Chip, New Endophenotypes & Functional Studies in CHARGE$163,697
R01 · FY2014 · AG · contact PI
Epidemiology of Dementia in the Framingham Study$1,347,693
R01 · FY2013 · AG · contact PI
AD Gene Discovery: Exome Chip, New Endophenotypes & Functional Studies in CHARGE$618,430
R01 · FY2013 · AG · contact PI
AD Gene Discovery: Exome Chip, New Endophenotypes & Functional Studies in CHARGE$263,120
R01 · FY2013 · AG · contact PI
Epidemiology of Dementia in the Framingham Study$93,919
R01 · FY2013 · AG · contact PI
Epidemiology of Dementia in the Framingham Study$1,408,800
R01 · FY2012 · AG
Epidemiology of Dementia in the Framingham Study$20,000
R01 · FY2012 · AG
Collaborative GWAS of Dementia, AD and related MRI and Cognitive Endophenotypes$536,308
R01 · FY2011 · AG · contact PI
Epidemiology of Dementia in the Framingham Study$1,371,239
R01 · FY2010 · AG
Collaborative GWAS of Dementia, AD and related MRI and Cognitive Endophenotypes$558,610
R01 · FY2010 · AG · contact PI
Neurotrophic Factors: Genetic Variation and Serum Levels in Brain Aging$366,737
R01 · FY2010 · AG · contact PI
Neurotrophic Factors: Genetic Variation and Serum Levels in Brain Aging$812,347
R01 · FY2009 · AG · contact PI
Collaborative GWAS of Dementia, AD and related MRI and Cognitive Endophenotypes$598,300
R01 · FY2009 · AG · contact PI